Activating KRAS mutations are produced by single substitutions of amino acids, and the resulting mutant proteins are associated with variable tumours, such as colorectal carcinoma, pancreatic ductal carcinoma, lung adenocarcinoma, and cholangiocarcinoma [7]. The gene discussed is KRAS; the disease is neoplasm.